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In patients with syphilis, central nervous system (CNS) involvement is often difficult to determine. In patients who also are in-
fected with human immunodeficiency virus (HIV), this is evenmore challenging, as cerebrospinal fluid (CSF) pleocytosis can be
attributed to HIV, syphilis, or both. Hence, this study investigated (i) CSF chemokine (C-X-Cmotif) ligand 13 (CXCL13) as a
potential marker to diagnose neurosyphilis in HIV-infected individuals and (ii) the added value of CSF CXCL13 to conventional
CSF biomarkers, such as the rapid plasma reagin test (RPR), in diagnosing neurosyphilis. We included 103 syphilis patients from
two centers in The Netherlands: 47 non-HIV-infected patients and 56 HIV-infected patients. A positive CSF-RPR was regarded
as the gold standard for neurosyphilis. CSF CXCL13 levels were significantly higher in neurosyphilis patients when neurosyphi-
lis was diagnosed by CSF-RPR (P 0.0002) than in the syphilis control group. The sensitivity and specificity of CSF CXCL13
(cutoff of 76.3 pg/ml) to diagnose neurosyphilis by using positive CSF-RPR as the gold standard were 50% and 90%, respectively.
CSF CXCL13 had an added value to CSF-RPR positivity in 70% of HIV-positive patients and in 33% of HIV-negative patients.
Our data show that CSF CXCL13might be a potential additional marker in neurosyphilis when other markers are not conclu-
sive. The added value of CSF CXCL13measurement to the current neurosyphilis gold standard appears to benefit HIV-positive
patients more than HIV-negative patients.
In 2007, the World Health Organization estimated an incidenceof 12million new infections with Treponema pallidum each year
worldwide (1). Invasion of the central nervous system (CNS) byT.
pallidummay occur during any disease stage of syphilis, leading
to the development of neurosyphilis in some patients (2, 3).
When dual infections with HIV and syphilis exist, the diagnos-
tic challenge increases. A positive cerebrospinal fluid (CSF)
Venereal Disease Research Laboratory test (VDRL) is generally
considered the gold standard for neurosyphilis (4); however,
several studies have clearly shown that a positive CSF rapid
plasma reagin test (RPR) is an alternative to CSF-VDRL (5, 6),
and RPR is also recommended by 2014 European guidelines
(IUSTI-2014) (7). When the CSF-RPR or CSF-VDRL is nega-
tive, the diagnosis relies on other markers, like CSF pleocytosis,
the CSF T. pallidum particle agglutination (TPPA) index, and
clinical signs and symptoms.
As the laboratory diagnosis of neurosyphilis is difficult, new
markers are needed, and CSF B cell chemoattractant chemokine
(C-X-C motif) ligand 13 (CXCL13) is currently forwarded as an
interestingmarker. CXCL13 has been demonstrated to be elevated
in B lymphocyte-rich CSF (8, 9). CSF CXCL13 has a higher sensi-
tivity than the established diagnostic markers for neuroborrelio-
sis, such as CSF pleocytosis and Borrelia-specific antibodies (10).
High numbers of B lymphocytes have also been observed in CSF
from patients with syphilitic meningitis (11). CXCL13 dictates
homing andmotility of B cells in lymphoid tissue (12), and it plays
a key role in the migration of B cells into the CSF (9). Hence,
studies of CSF CXCL13 as a diagnostic marker for neurosyphilis
are warranted. Recently, it has been shown that the CSF CXCL13
concentration was particularly useful for the diagnosis of neu-
rosyphilis in HIV-infected patients independent of CSF pleocyto-
sis andmarkers of HIV disease (13). So far, there is only one study
available.
Therefore, we aimed to (i) investigate CSF CXCL13 as a
potential marker for neurosyphilis in HIV-infected and HIV-
seronegative individuals and (ii) investigate the added value of
CSF CXCL13 to CSF-RPR in diagnosing neurosyphilis.
MATERIALS AND METHODS
Study population. One hundred and seven patients from two centers in
The Netherlands (VU University Medical Center [VUMC] and Radboud
University Medical Center) were selected in the period of March 2005 to
February 2012. The study included patients with confirmed syphilis on
the basis of a positive TPPA test. One hundred and three patients under-
went an HIV test, and 56 of themwere HIV seropositive and 47 were HIV
seronegative. The remaining 4 patients without anHIV test were excluded
from this study. All of the 103 patients were subjected to a lumbar punc-
ture; therefore, routine CSF samples were used for the quantification of
CXCL13. The CSF samples were kept frozen at 80°C, and all samples
and patients histories were anonymized, making it impossible to trace
back the patients for further clinical data. Patient characteristics are
depicted in Table 1. In this study, we considered a positive CSF-RPR as
the gold standard for diagnosing neurosyphilis (5, 6). According to the
Dutch legislature (Evaluation of the Dutch Medical Treatment Act
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[WGBO]), our study qualified for ethical clearance exemption, since it
is a nonprofit, scientific study and its purpose is to improve the quality
of diagnosis.
Laboratory tests. CXCL13 was measured in CSF using the human
CXCL13/BLC/BCA-1 Quantikine enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems,Minneapolis,MN) according to themanufac-
turer’s instructions. The intraassay coefficient of variation (CV) was be-
tween 1.4% and 4.3%; the interassay CV was higher (26%) but could be
measured only at the low end of the calibration curve (due to insufficient
CSF samples with high CXCL13 concentrations). Recovery was between
95% and 105%. The assay was linear up to 1,000 pg/ml. The lower detec-
tion limit was 7.8 pg/ml. Samples below the detection limit were recoded
as 0 pg/ml.
The white blood cell count was performed by using standard flow
cytometric immunophenotyping.
Rapid plasma reagin in CSF was measured using the rapid plasma
reagin card test (Biokit S.A., Barcelona, Spain). A TPPA test (Fujirebio
Inc., Japan) was used to test specific treponemal antibody in CSF.
Immunonephelometry using a Beckman Immage nephelometer was
used to measure CSF and serum albumin.
Statistical analysis.Data analysis was performed using SPSS (SPSS 20,
Inc., Chicago, IL, USA). CXCL13 levels were compared between different
patient groups (patients with and without HIV and patients with and
without neurosyphilis), using Mann-Whitney U test statistics. The sensi-
tivity and specificity of CSF CXCL13 were calculated using a 2-by-2 table.
The added value was taken as a percentage of nonneurosyphilis patients
(negative by CSF-RPR) that tested positive for CSF CXCL13 with a cutoff
value of 76.3 pg/ml divided by the total number of patients with a
positive CSF-RPR. The cutoff for the clinical significance level of CXCL13
was defined as any value above the 25th percentile of the positive CXCL13
values and thereby set at 76.3 pg/ml. A P value of 0.05 was considered
statistically significant.
RESULTS
Patient characteristics. Baseline characteristics of the study pop-
ulation are summarized in Table 1. The study included 103 syph-
ilis patients with a median age of 44 years, 56 were HIV infected,
and 47 were HIV seronegative. The CSF-RPR was positive in 6/47
(13%) HIV-negative patients and in 10/56 (18%) HIV-positive
patients. Sixteen percent of all patients were categorized as neu-
rosyphilis positive according to a positive CSF-RPR. Clinical signs
or symptoms were present in 33 (39%) patients; these included
neurological, psychiatric, acoustic, and ophthalmological signs
and symptoms. Fifty-two patients (61%) had no neurological or
psychiatric symptoms, while for 19 patients, clinical data were
missing.
In all patients, CSF CXCL13 levels were significantly higher in
patients with established neurosyphilis as diagnosed by positive
CSF-RPR (median of 177 pg/ml, P 0.0002) than in patients with
syphilis but without CNS involvement (median of 0 pg/ml) (Fig.
1a). CSF CXCL13 levels were similar in all HIV-infected and non-
HIV-infected patients (both medians were 0 pg/ml, P  0.16).
However, CSF CXCL13 levels were elevated in HIV-infected (me-
dian of 177 pg/ml, P 0.014) and non-HIV-infected (median of
783 pg/ml, P  0.005) patients with neurosyphilis compared to
those in the syphilis control groups (both medians were 0 pg/ml)
(Fig. 1b).
Regarding RPR positivity as the gold standard, a sensitivity of
50% and a specificity of 90%were obtained when using the cutoff
of 76.3 pg/ml CSF CXCL13 as a marker for the diagnosis of neu-
rosyphilis.
The assumed added value of CSF CXCL13 to CSF-RPR posi-
tivity was the diagnosis of 9/16 (56%) patients. The added value is
higher in HIV-positive patients (7/10 [70%]) than in HIV-nega-
tive patients (2/6 [33%]).
DISCUSSION
The diagnosis of asymptomatic neurosyphilis is based on CSF ab-
normalities, but in individuals infected by both syphilis and HIV,
the diagnosis may be difficult because of overlapping diagnostic
test results. In this study, we demonstrated significantly elevated
levels of CSF CXCL13 in neurosyphilis patients. These data sup-
port the observations made by Marra et el. (13). Using a cutoff
level of 76.3 pg/ml (positive CXCL13 levels above the 25th percen-
tile), we estimated the added value of CSF CXCL13 as a diagnostic
marker for neurosyphilis to be higher in HIV-positive patients
than in HIV-negative patients for diagnosing neurosyphilis.
Only one study similar to ours has been performed, in which
the authors included HIV patients only (13). Unlike Marra et al.
(13), we included both HIV-infected and non-HIV-infected pa-
tients.We clearly showed the added value of CSFCXCL13 to CSF-
RPR, and we also showed that HIV-infected patients benefited
more from CSF CXCL13 as an added marker for diagnosis of
neurosyphilis. Cepok et al. showed that HIV infection triggers an
early profound B cell response in CNS, which serves as the main
virus-related B cell subset in the CSF (14), and B cells are themain
source of CSF CXCL13 (8, 13). However, Bremell et al. showed
that CSF CXCL13 was not increased in HIV-infected patients (15),
and we did not observe elevated CSF CXCL13 concentrations in the
HIV- andT. pallidum-coinfected control groupwith anegativeCSF-
RPR result. Even though the effect of HIV alone was not proven in
our study, Bremell et al. (15) datamay suggests that there is an added
CSF CXCL13 release in neurosyphilis patients coinfected with HIV,
TABLE 1 Patients’ characteristics
Characteristic of syphilis and
neurosyphilis patients (n 103) Value
No. (%) of males 93 (90)
Median (minimum–maximum) age in yrs 44 (20–84)
No. (%) of patients by HIV status
Positive 56 (54)
Negative 47 (46)
Median (minimum–maximum) HIV load
in copies/ml
22 10E3 (20–300 10E4)
Median (minimum–maximum) CSF
CXCL13 concn in pg/ml
HIV-positive patients 0 (0–15,480)
HIV-negative patients 0 (0–11,598)
Median (minimum–maximum) CSF
pleocytosis in cells/mm3
HIV-positive patients 5 (0–150)
HIV-negative patients 1 (0–222)
Median (minimum–maximum) CSF
protein concn in mg/liter
HIV-positive patients 406 (150–1,511)
HIV-negative patients 398 (150–3,088)
No. (%) of patients positive by reactive
serum-RPR (1:4)
74 (72)
No. (%) of patients positive by reactive
CSF-RPR (1:2)
16 (16)
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hence the observed added benefit of CSF CXCL13 in HIV-infected
patients in diagnosing neurosyphilis.However, we cannot strictly ex-
clude other causes for high or detectable CXCL13.
Marra and colleagues analyzed two CXCL13 cutoffs; the lower
cutoff (10 pg/ml) showed a high sensitivity, and the higher cutoff
(250 pg/ml) showed a high specificity (13). In our study, 76.3
pg/ml is a reasonable cutoff value and can be used to distinguish
between patients with and without neurosyphilis. The 76.3 pg/ml
cutoff showed a sensitivity and specificity of 50% and 90%,
respectively. Even though CSF CXCL13 concentration is not a
confirmatory test, we assume on the basis of serological syphilis
and pathogenesis of CXCL13 that CSF CXCL13 concentration
can contribute to the diagnosis of neurosyphilis. Furthermore, the
use of CSF CXCL13 concentration for the diagnosis of neurolog-
ical infections with spirochetes, such as neuroborreliosis and also
neurosyphilis, has been shown before (13, 16). However, the cur-
rent study demonstrates an added value of CXCL13 concentration
as a marker in the diagnosis of neurosyphilis, which increases in
HIV-infected patients.
A limitation of this study is that we could include only pa-
tients from whom CSF was obtained. Syphilis patients and HIV
patients without suspected neurological disease were not in-
cluded, implying possible selection bias. However, our data did
not find any difference in CXCL13 levels between patients with
and without neurological symptoms, implying that this bias
probably is not that important. A lack of clinical data, such as
treatment for syphilis or treatment with drugs active against T.
pallidum or other etiologies that may affect CSF CXCL13 levels,
also limits our study.
In conclusion, CSF CXCL13 may be a potential marker for
neurosyphilis, as demonstrated by elevated levels in patients with
suspected neurosyphilis according to a positive CSF-RPR. The
added value of CSF CXCL13 in the diagnosis of neurosyphilis, in
addition to the easy and cheap CSF-RPR, benefits HIV-positive
patients more than non-HIV patients.
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